SAFETY OF MISOPROSTOL IN SECOND TRIMESTER MISCARRIAGES IN PATIENTS WITH PREVIOUS UTERINE SCARS
Main Article Content
Abstract
Objective: To assess the safety of Misoprostol in mid-trimester miscarriages in patients with previous scars.
Materials and Methods: This was a cross-sectional comparative study conducted in the Department of Gynaecology and Obstetrics, Lady Reading Hospital, from January 2021 to December 2021. Two-hundred patients with second-trimester miscarriages were included in the study. They were divided into two groups, 100 patients with no previous scar as the control group and another 100 patients with a previous scar as the study group. Patients having an incomplete abortion, gestational trophoblastic disease, and more than one scar were excluded from the study. Misoprostol doses were kept vaginally in both groups. The doses were kept according to the gestational period of 13 to 24 weeks following the local protocol which was comparable with the FIGO protocol. Data analysis was done using SPSS-24.
Results: The Demographic features of patients of the two groups, were comparable for maternal Age (26±5.3 Years versus 25±4.9 years), Gestational Age in weeks of (18±1.3 weeks versus117±1.6 weeks) Gravidity (4.5±1.6 versus 4.9±1.2) and of Parity (3.4 ±1.4 versus 3.6 ±1.1) which showed no significant difference with respect to age, parity and gestational age. The period needed for successful TOP was 18 hours in the control group whereas it was 36 hours in the scarred uterus with half doses. Successful termination was observed in 61% of the study group with the scared uterus and 72% in the control group.
Conclusion: Our study concluded that misoprostol is safe and effective in the termination of second-trimester miscarriages with a scarred uterus.
Keywords: Misoprostol, Miscarriage, Previous Uterine Scar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in the Journal of Medical Sciences (JMS) are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under the CC BY 4.0 license, author(s) retain the ownership of the copyright publishing rights without restrictions for their content, and allow others to copy, use, print, share, modify, and distribute the content of the article even for commercial purposes as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers for this purpose. Appropriate attribution can be provided by simply citing the original article. The corresponding author has the right to grant on behalf of all authors, a worldwide license to JMS and its licensees in all forms, formats, and media (whether known now or created in the future), The corresponding author must certify and warrant the authorship and proprietorship and should declare that he/she has not granted or assigned any of the article’s rights to any other person or body.
The corresponding author must compensate the journal for any costs, expenses, or damages that the JMS may incur as a result of any breach of these warranties including any intentional or unintentional errors, omissions, copyright issues, or plagiarism. The editorial office must be notified upon submission if an article contains materials like text, pictures, tables, or graphs from other copyrighted sources. The JMS reserves the right to remove any images, figures, tables, or other content, from any article, whether before or after publication, if concerns are raised about copyright, license, or permissions and the authors are unable to provide documentation confirming that appropriate permissions were obtained for publication of the content in question.